Fracheboud J, de Koning H J, Beemsterboer P M, Boer R, Verbeek A L, Hendriks J H, van Ineveld B M, Broeders M J, de Bruyn A E, van der Maas P J
Department of Public Health, Erasmus University Rotterdam, The Netherlands.
Br J Cancer. 1999 Nov;81(5):912-7. doi: 10.1038/sj.bjc.6690786.
The nationwide breast cancer screening programme in The Netherlands for women aged 50-69 started in 1989. In our study we assessed the occurrence and stage distribution of interval cancers in women screened during 1990-1993. Records of 0.84 million screened women were linked to the regional cancer registries yielding a follow-up of at least 2.5 years. Age-adjusted incidence rates and relative (proportionate) incidences per tumour size including ductal carcinoma in-situ were calculated for screen-detected and interval cancers, and cancers in not (yet) screened women, comparing them with published data from the UK regions North West and East Anglia. In total 1527 interval cancers were identified: 0.95 and 0.99 per 1000 woman-years of follow-up in the 2-year interval after initial and subsequent screens respectively. In the first year after initial screening interval cancers amounted to 27% (26% after subsequent screens) of underlying incidence, and in the second year to 52% (55%). Generally, interval cancers had a more favourable tumour size distribution than breast cancer in not (yet) screened women. The Dutch programme detected relatively less (favourable) invasive cancers in initial screens than the UK programme, whereas the number of interval cancers confirms UK findings. Measures should be considered to improve the detection of small invasive cancers and to reduce false-negative rates, even if this will lead to increasing referral rates.
荷兰针对50 - 69岁女性的全国性乳腺癌筛查项目始于1989年。在我们的研究中,我们评估了1990 - 1993年期间接受筛查的女性中间期癌的发生率和分期分布。84万接受筛查女性的记录与区域癌症登记处相关联,从而实现了至少2.5年的随访。计算了筛查发现的癌、间期癌以及未(尚)接受筛查女性的癌症按年龄调整的发病率和包括导管原位癌在内的每种肿瘤大小的相对(比例)发病率,并将其与英国西北部和东安格利亚地区公布的数据进行比较。总共识别出1527例间期癌:初次筛查后的2年间期内,每1000名女性年随访中有0.95例;后续筛查后的2年间期内,每1000名女性年随访中有0.99例。初次筛查后的第一年,间期癌占潜在发病率的27%(后续筛查后为26%),第二年占52%(55%)。一般来说,与未(尚)接受筛查女性的乳腺癌相比,间期癌的肿瘤大小分布更有利。荷兰的项目在初次筛查中检测到的(预后较好的)浸润性癌比英国项目相对较少,而间期癌的数量证实了英国的研究结果。应考虑采取措施来提高小浸润性癌的检测率并降低假阴性率,即使这会导致转诊率上升。